RBM3 protein in colorectal cancer prognostics

US9416176B2 · kind B2 · utility

Assignee

• Atlas Antibodies AB · SE

Inventors

• Mathias Uhlen · Uppsala, SE
• Fredrik Pontén · Uppsala, SE
• Karin Jirström · Malmö, SE

Key dates

• Filing date: Apr 9, 2014
• Grant date: Aug 16, 2016
• Expiry date: Sep 18, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.